Related Experiment Video
Updated: May 26, 2026
08:30
Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation
Published on: August 14, 2017
[ADAMTS13, von Willebrand factor specific cleaving protease].
1Service -D'hématologie Biologique, Hôpital Antoine Béclère, Groupe Hospitalier Paris-Sud, AP-HP, 157, rue de la Porte de Trivaux, 92140 Clamart, France. agnes.veyradier@abc.aphp.fr
Medecine Sciences : M/S
|December 24, 2011
Summary
ADAMTS13 enzyme deficiency causes thrombotic thrombocytopenic purpura (TTP). Understanding ADAMTS13 structure and function is key to developing new TTP treatments using plasma-derived or recombinant ADAMTS13.
Area of Science:
- Biochemistry
- Hematology
- Genetics
Background:
- ADAMTS13 (A disintegrin and metalloprotease with thrombospondin type 1 repeats) is the key enzyme cleaving von Willebrand factor (VWF).
- VWF mediates platelet adhesion and aggregation, crucial for hemostasis.
- ADAMTS13 regulates VWF size, controlling its adhesive properties.
Purpose of the Study:
- To highlight the critical role of ADAMTS13 in VWF regulation.
- To discuss the association between ADAMTS13 deficiency and thrombotic thrombocytopenic purpura (TTP).
- To emphasize the need for further research into ADAMTS13 structure-function relationships for therapeutic development.
Main Methods:
- Purification of ADAMTS13 from human plasma.
- Cloning of the ADAMTS13 gene.
- Clinical characterization of TTP patients.
Main Results:
- Severe ADAMTS13 deficiency (<10% activity) is linked to most TTP cases.
- TTP involves microvascular thrombosis due to dysregulated VWF.
- Acquired TTP (90%) results from auto-antibodies; inherited TTP stems from gene mutations.
Conclusions:
- ADAMTS13 functional deficiency is central to TTP pathogenesis.
- Investigating ADAMTS13 structure and function is vital for TTP treatment.
- Plasma-purified or recombinant ADAMTS13 holds therapeutic potential for TTP.
Related Concept Videos
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.